Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	112.81	119.91	120.79	113.83	147.79	130.46
Revenue Growth (YoY)	30.55%	-0.73%	6.12%	-22.98%	13.29%	13.83%
Cost of Revenue	50.45	43.3	37.51	40.61	58.39	61.43
Gross Profit	62.36	76.6	83.28	73.22	89.41	69.03
Selling, General & Admin	48.33	55.56	59.93	51.23	74.1	56.74
Research & Development	25.83	25.54	21.76	18.32	27.33	22.02
Operating Expenses	74.16	81.1	81.69	69.55	101.42	78.76
Operating Income	-11.8	-4.5	1.59	3.67	-12.02	-9.73
Interest Expense	-	-	-	-	-0.19	-0.3
Interest & Investment Income	2.37	2.34	2.31	0.65	-	-
EBT Excluding Unusual Items	-9.43	-2.16	3.9	4.32	-12.2	-10.03
Merger & Restructuring Charges	-0.61	-0.61	-0.75	-	-6.47	-4.1
Impairment of Goodwill	-	-	-	-	-	-42.52
Asset Writedown	-	-	-	-	-	-2.44
Other Unusual Items	-	-	-	-	21.1	30.47
Pretax Income	-10.03	-2.76	3.16	4.32	2.43	-28.62
Income Tax Expense	4.23	6.06	6.6	2.12	-1.71	-4.64
Earnings From Continuing Operations	-14.27	-8.83	-3.44	2.2	4.13	-23.98
Earnings From Discontinued Operations	-18.77	-47.56	-79.23	-17.06	-	-
Net Income	-33.04	-56.39	-82.67	-14.86	4.13	-23.98
Net Income to Common	-33.04	-56.39	-82.67	-14.86	4.13	-23.98
Shares Outstanding (Basic)	14	15	15	15	14	14
Shares Outstanding (Diluted)	14	15	15	15	15	14
Shares Change (YoY)	-2.20%	0.44%	0.65%	-0.50%	2.90%	-1.06%
EPS (Basic)	-2.29	-3.83	-5.64	-1.02	0.29	-1.69
EPS (Diluted)	-2.29	-3.83	-5.64	-1.02	0.28	-1.69
Free Cash Flow	0.65	-2.33	-7.22	-3.08	3.25	11.44
Free Cash Flow Per Share	0.04	-0.16	-0.49	-0.21	0.22	0.80
Gross Margin	55.28%	63.89%	68.95%	64.33%	60.49%	52.91%
Operating Margin	-10.46%	-3.75%	1.32%	3.22%	-8.13%	-7.46%
Profit Margin	-29.29%	-47.02%	-68.44%	-13.05%	2.80%	-18.38%
Free Cash Flow Margin	0.57%	-1.94%	-5.97%	-2.70%	2.20%	8.77%
EBITDA	-3.67	3.63	15.81	18.16	2.3	3.74
EBITDA Margin	-3.25%	3.02%	13.09%	15.95%	1.56%	2.86%
D&A For EBITDA	8.13	8.12	14.22	14.49	14.32	13.46
EBIT	-11.8	-4.5	1.59	3.67	-12.02	-9.73
EBIT Margin	-10.46%	-3.75%	1.32%	3.22%	-8.13%	-7.46%
Effective Tax Rate	-	-	208.97%	49.12%	-	-

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q